Pharmasset (VRUS) Reports Q2 Loss of $0.59
More News related to VRUS
- Unusual 11 Mid-Day Movers 11/18: ABK, LZB, NLST, LDK Higher; ONCY, NANO, EXEL, VRUS Lower
- Bank of America Initiates Coverage on Pharmasset (VRUS) with a Buy.
- Pharmasset to Present at Lazard Capital Markets Healthcare Conference
- InterMune (ITMN) Higher Following INFORM-1 Trial Data
- Baird Maintains an 'Outperform' on Pharmasset (VRUS); Year Ahead is Catalyst-Rich
Pharmasset, Inc. (Nasdaq: VRUS) reports Q2 loss of $0.59, 11 cents worse than the analyst estimate of ($0.48). Revenue for the quarter was $1.9 million, versus the consensus of $5.61 million.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
